רווח תפעולי לפני פחת: mainzbiomed.com (MYNZ)

Consistent demand for colorectal cancer screening via ColoAlert systems provides Mainz Biomed N.V. (MYNZ) with a steady cash flow. The absolute EBITDA level demonstrates current operating profit dynamics, where the value of 0.00 reflects this status. Business efficiency is based on the automation of biomarker tests and growing physician confidence across Europe and the US.

This indicator reflects the actual liquidity inflow from the core operations of Mainz Biomed N.V. (MYNZ), eliminating the temporary gaps of standard reporting through daily cash flow monitoring. By analyzing quarterly EBITDA, investors can see how the supply of diagnostic tests to clinics in the US and Europe converts into actual capital, allowing for an objective assessment of the business's resilience to market downturns.